Hypertension and diabetes

Journal of Human Hypertension

Volumn 16, Issue , 2002, Pages S56-S60

  Kaplan, N M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diabetes; Hypertension

Indexed keywords

ALCOHOL DRINKING; ANTIHYPERTENSIVE AGENTS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; EXERCISE; HUMANS; HYPERTENSION; OBESITY; RISK FACTORS; SMOKING CESSATION; SODIUM CHLORIDE, DIETARY; WEIGHT LOSS;

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LONG ACTING DRUG; LOOP DIURETIC AGENT; LOSARTAN; MEDROXYPROGESTERONE; NISOLDIPINE; NITRENDIPINE; PLACEBO; RAMAPRIL; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

AGING; ALCOHOL CONSUMPTION; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ESTROGEN THERAPY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; KINESIOTHERAPY; LIFESTYLE; OBESITY; PREVALENCE; SMOKING CESSATION; SODIUM RESTRICTION; WEIGHT REDUCTION;

EID: 0036229012     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001344     Document Type: Article

References (33)

1. Amri K et al. Adverse effects of hyperglycemia on kidney development in rats. Diabetes 1999; 48: 2240-2245.
2. Mokdad AH et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999; 282: 1519-1522.
3. Samaras K, Campbell LV. Increasing incidence of type 2 diabetes in the third millennium. Diabetes Care 2000; 23: 441-442.
4. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341: 427-434.
5. Wei M et al. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. Ann Intern Med 1999; 130: 89-96.
6. He J et al. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 1999; 282: 2027-2034.
7. Valmadrid CT et al. Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus. JAMA 1999; 282: 239-246.
8. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hyper-tension:$principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
9. Gaede P et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
10. Lievre M et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Diabetes Care 2000; 23: B65-B71.
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascu-lar and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
12. Giordano M et al. Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists and a-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995; 44: 665-671.
13. Jollis JG et al. Calcium channel blockers and mortality in elderly patients with myocardial infarction. Arch Intern Med 1999; 159: 2341-2348.
14. Tuomilehto J et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-684.
15. Fogari R et al. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999; 13: 47-53.
16. Mathiesen ER et al. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999; 319: 24-25.
17. Hansson L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
18. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mel-litus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 246, 253-259.
19. Pitt B et al. Randomised trial of losartan versus captop-ril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE). Lancet 1997; 349: 747-752.
20. Pitt B et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
21. Bakris GL et al. Differential effects of valsartan (V) and lisinopril (L) on potassium (K+) homeostasis in hypertensive patients with nephropathy. Am J Hypertens 1999; 12: 36A.
22. Fogari R et al. Adding losartan to lisinopril therapy in patients with hypertension: assessment by 24-hour ambulatory blood pressure monitoring. Curr Ther Res 1999; 60: 326.
23. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-1132.
24. Bakris GL. Maximizing cardiorenal benefit in the management of hypertension: achieving blood pressure goals. J Clin Hypertens 1999; 1: 141-147.
25. Kaplan NM. Management of hypertension in patients with type 2 diabetic mellitus: guidelines based on current evidence. Ann Intern Med 2001; 135: 1079-1083.
26. Chan JCN et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.
27. Velussi M et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216-222.
28. Estacio RO et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
29. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54: 1283-1289.
30. Tatti P et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
31. Hattori Y, Hattori S, Kasai K. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. Hypertension 1999; 33: 943-948.
32. Nazzaro P et al. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension 1999; 33: 719-725.
33. Samaras K et al. Effects of postmenopausal hormone replacement therapy on central abdominal fat, gly-cemic control, lipid metabolism and vascular factors in type 2 diabetes. Diabetes Care 1999; 22: 1401-1407.